Consensus on the treatment of allergic asthma with sublingual house dust mite immunotherapy in the field of pneumology-Reference-Cited by-同舟云学术

Consensus on the treatment of allergic asthma with sublingual house dust mite immunotherapy in the field of pneumology

Published:2021-08-18 Issue:10 Volume:15 Page:1245-1249
ISSN:1747-6348
Container-title:Expert Review of Respiratory Medicine
language:en
Short-container-title:Expert Review of Respiratory Medicine

Author:

Plaza Vicente¹,Arnedillo Aurelio²,Blanco-Aparicio Marina³,Ignacio José María⁴,Urrutia Isabel⁵

Affiliation:

1. Director del Comité Ejecutivo de la Guía Española Para el Manejo del Asma (GEMA), Servei de Pneumologia i Al·lèrgia, Hospital de la Santa Creu i Sant Pau, Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau), Universitat Autònoma de Barcelona, Barcelona, Spain

2. UGC de Neumología, Alergia y Cirugía Torácica, Hospital Universitario Puerta del Mar, Cádiz, Spain

3. Coordinadora del Área de Asma de SEPAR, Servicio de Neumología, Complejo Hospitalario Universitario A Coruña, A Coruña, Spain

4. Servicio de Neumología, Hospital Quirónsalud Marbella, Marbella, Málaga, Spain

5. Unidad de Asma, Hospital Universitario de Galdakao, Galdakao, Bizkaia, Spain

Funder

ALK

Publisher

Informa UK Limited

Subject

Public Health, Environmental and Occupational Health,Pulmonary and Respiratory Medicine,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/17476348.2021.1942846

Reference15 articles.

1. Burden of rhinitis in children with asthma

2. Can Guideline-defined Asthma Control Be Achieved?

3. SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial

4. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: A randomized, double-blind, placebo-controlled trial